Blog

Jun 17, 2025

Privacy-By-Design Is Non-Negotiable in Clinical AI

Inside OASYS NOW’s commitment to building ethical, secure, and compliant infrastructure for the future of medicine.

Nov 21, 2024

OASYS NOW Wins Slush 100

Europe’s top healthtech startup, recognized for redefining patient-first, privacy-powered AI.

Trusted by Experts

From clinical trial sites to data governance teams, OASYS NOW supports those driving precision care forward — with privacy-first technology you can trust.

ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.
Dr. Niels Prins
Neurologist & CEO
We matched hundreds of Alzheimer’s patients with over 90% accuracy, including from scanned referral letters. ELaiGIBLE explains every match, so we trust what we see.
Janne Heuvelmans
Research physician & Data and Systems manager
OASYS ELaiGIBLE is the best tool on the market for patient identification and pre-screening by a thousand miles, and seeing their speed of development, I can only imagine how they're going empower organizations with their cutting edge tools.
Frank Peters
Patient Recruitment Specialist
It works across all our systems, even scanned notes and PDFs. Finally, a tool that respects the real mess of real-world data. It’s ISO27001 and NEN7510 compliant out of the box, with a full audit trail. That makes my job easier and safer.
Database Manager, Trial Site
DB Manager
No more building manual queries. We just upload the protocol, ELaiGIBLE takes care of the rest.
Pre-screening Specialist
Pre-screening Specialist
ELaiGIBLE has become a key driver in how we accelerate and scale clinical research. It’s an indispensable part of our strategy moving forward.
MD & CEO
Top Trial Site

Trusted by Experts

From clinical trial sites to data governance teams, OASYS NOW supports those driving precision care forward — with privacy-first technology you can trust.

ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.
Dr. Niels Prins
Neurologist & CEO
We matched hundreds of Alzheimer’s patients with over 90% accuracy, including from scanned referral letters. ELaiGIBLE explains every match, so we trust what we see.
Janne Heuvelmans
Research physician & Data and Systems manager
OASYS ELaiGIBLE is the best tool on the market for patient identification and pre-screening by a thousand miles, and seeing their speed of development, I can only imagine how they're going empower organizations with their cutting edge tools.
Frank Peters
Patient Recruitment Specialist
It works across all our systems, even scanned notes and PDFs. Finally, a tool that respects the real mess of real-world data. It’s ISO27001 and NEN7510 compliant out of the box, with a full audit trail. That makes my job easier and safer.
Database Manager, Trial Site
DB Manager
No more building manual queries. We just upload the protocol, ELaiGIBLE takes care of the rest.
Pre-screening Specialist
Pre-screening Specialist
ELaiGIBLE has become a key driver in how we accelerate and scale clinical research. It’s an indispensable part of our strategy moving forward.
MD & CEO
Top Trial Site

Trusted by Experts

From clinical trial sites to data governance teams, OASYS NOW supports those driving precision care forward — with privacy-first technology you can trust.

ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.
Dr. Niels Prins
Neurologist & CEO
We matched hundreds of Alzheimer’s patients with over 90% accuracy, including from scanned referral letters. ELaiGIBLE explains every match, so we trust what we see.
Janne Heuvelmans
Research physician & Data and Systems manager
OASYS ELaiGIBLE is the best tool on the market for patient identification and pre-screening by a thousand miles, and seeing their speed of development, I can only imagine how they're going empower organizations with their cutting edge tools.
Frank Peters
Patient Recruitment Specialist
It works across all our systems, even scanned notes and PDFs. Finally, a tool that respects the real mess of real-world data. It’s ISO27001 and NEN7510 compliant out of the box, with a full audit trail. That makes my job easier and safer.
Database Manager, Trial Site
DB Manager
No more building manual queries. We just upload the protocol, ELaiGIBLE takes care of the rest.
Pre-screening Specialist
Pre-screening Specialist
ELaiGIBLE has become a key driver in how we accelerate and scale clinical research. It’s an indispensable part of our strategy moving forward.
MD & CEO
Top Trial Site

Trusted by Experts

From clinical trial sites to data governance teams, OASYS NOW supports those driving precision care forward — with privacy-first technology you can trust.

ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.
Dr. Niels Prins
Neurologist & CEO
We matched hundreds of Alzheimer’s patients with over 90% accuracy, including from scanned referral letters. ELaiGIBLE explains every match, so we trust what we see.
Janne Heuvelmans
Research physician & Data and Systems manager
OASYS ELaiGIBLE is the best tool on the market for patient identification and pre-screening by a thousand miles, and seeing their speed of development, I can only imagine how they're going empower organizations with their cutting edge tools.
Frank Peters
Patient Recruitment Specialist
It works across all our systems, even scanned notes and PDFs. Finally, a tool that respects the real mess of real-world data. It’s ISO27001 and NEN7510 compliant out of the box, with a full audit trail. That makes my job easier and safer.
Database Manager, Trial Site
DB Manager
No more building manual queries. We just upload the protocol, ELaiGIBLE takes care of the rest.
Pre-screening Specialist
Pre-screening Specialist
ELaiGIBLE has become a key driver in how we accelerate and scale clinical research. It’s an indispensable part of our strategy moving forward.
MD & CEO
Top Trial Site